2025
All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.
Gottlieb A, Crooke Kwiatkowski H, Semeco J, Lakshminarasimhan B, Strober B, Lebwohl M. All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis. Journal Of Psoriasis And Psoriatic Arthritis 2025, 24755303251344155. PMID: 40454110, PMCID: PMC12125009, DOI: 10.1177/24755303251344155.Peer-Reviewed Original ResearchAll-cause mortalityGeneralized pustular psoriasisMortality riskGeneral populationMaximum follow-upFollow-upElevated mortality riskPlaque psoriasisPustular psoriasisAll-causeMortality burdenClaims dataDays post-indexIndex dateMedical claimsPopulation of patientsObservational studyUS claims dataUS-basedPropensity score matchingCohortLimited literaturePost-indexBalance covariatesMortalityTemporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer
Jairam V, Lindsay M, Soulos P, Gross C, Prsic E, Baum L, Park H. Temporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer. Journal Of Pain And Symptom Management 2025 PMID: 40403779, DOI: 10.1016/j.jpainsymman.2025.05.007.Peer-Reviewed Original ResearchPain-related ED visitsOpioid useGabapentinoid useOpioid-related encountersAdvanced cancerOpioid prescribingED visitsAdvanced solid tumor cancersEnd Results (SEER)-Medicare databaseHigh-risk opioid useNonopioid pain medicationsMultivariate logistic regression modelNon-cancer patientsSolid tumor cancersPain controlPain medicationInvestigate time trendsIndex dateLogistic regression modelsCancer cohortOpioidNoncancer patientsOpioid epidemicPatientsNoncancer cohortTreatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.
Lachowiez C, Barcellos A, Zettler C, Belli A, Fernandes L, Hansen E, Wang C, Owusu H, Zeidan A, Stein E, Swords R. Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy. JCO Oncology Practice 2025, op2400983. PMID: 40340477, DOI: 10.1200/op-24-00983.Peer-Reviewed Original ResearchVEN-based therapyTreatment patternsTime to next treatmentVenetoclax-based therapyVIALE-A trialEvent-free survivalLow-intensity regimensKaplan-Meier methodOutcomes of patientsInduction chemotherapyDiagnosed AMLIntensive chemotherapySecond-lineMutation statusFirst-lineInvestigational therapiesIndex dateMolecular subgroupsFLT3</i>-ITDNext treatmentDose informationTherapyAMLPatientsNovel treatmentTarget Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-cause mortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination statusEffectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Lin H, Bui D, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, O'Hare A, Viglianti E, Aslan M, Bajema K. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation. Annals Of Internal Medicine 2025, 178: 348-359. PMID: 39903865, DOI: 10.7326/annals-24-01015.Peer-Reviewed Original ResearchConceptsU.S. Department of Veterans AffairsDepartment of Veterans AffairsMatched index dateVaccine effectivenessTarget trial emulationSARS-CoV-2-associated deathsRandomized controlled trialsCOVID-19 vaccineSARS-CoV-2-related outcomesSARS-CoV-2 testingVeterans AffairsResidual confoundingAbsence of randomized controlled trialsLong-term follow-upDocumented SARS-CoV-2 infectionTrial emulationUnvaccinated personsIndex datePositive resultsControlled trialsCOVID-19SARS-CoV-2 infectionIncomplete captureHospitalDocumented infectionRisk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study
Janetzki J, Kim J, Minty E, Lee J, Morales D, Khera R, Kim C, Alshammari T, DuVall S, Matheny M, Falconer T, Kim S, Phan T, Nguyen P, Hsu M, Hsu J, Park R, Man K, Seager S, Van Zandt M, Gilbert J, Ryan P, Schuemie M, Suchard M, Hripcsak G, Pratt N, You S. Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study. EClinicalMedicine 2025, 81: 103096. PMID: 39975698, PMCID: PMC11836508, DOI: 10.1016/j.eclinm.2025.103096.Peer-Reviewed Original ResearchUrinary tract infectionRisk of aortic aneurysmTreat urinary tract infectionsOutpatient settingAortic aneurysmIndex dateCohort studyHazard ratioUrinary tract infection treatmentYonsei University College of MedicineRetrospective cohort studyPropensity scoreCox proportional hazards modelsPropensity-matched pairsRandom-effects meta-analysisProportional hazards modelNational Health and Medical Research Council (NHMRCUniversity College of MedicineSystemic fluoroquinolonesTract infectionsNo significant differenceBayesian random-effects meta-analysisFollow-upPrimary outcomeIncreased riskAssociation of delayed asthma diagnosis with asthma exacerbations in children
Wi C, Ryu E, King K, Kwon J, Bublitz J, Park M, Chiarella S, Greenwood J, Pongdee T, Myers L, Nordlund B, Sohn S, Sagheb E, Kshatriya B, Watson D, Liu H, Sheares B, Davis C, Schulz W, Juhn Y. Association of delayed asthma diagnosis with asthma exacerbations in children. Journal Of Allergy And Clinical Immunology Global 2025, 4: 100409. PMID: 40008091, PMCID: PMC11851198, DOI: 10.1016/j.jacig.2025.100409.Peer-Reviewed Original ResearchElectronic health recordsDiagnosis of asthmaAsthma diagnosisAsthma exacerbationsRisk of AEPredetermined Asthma CriteriaDiagnosis of childhood asthmaChildhood asthma managementIncreased riskCox proportional hazards modelsIncreased risk of AECare qualityAsthma outcomesHealth recordsProportional hazards modelAsthma managementChildhood asthmaBirth cohortAsthma severityDiagnosis statusIndex dateIdentifying childrenPrimary outcomeNatural language processing algorithmsHazards model
2024
Prevalent Atherosclerotic Cardiovascular Disease Among Veterans by Sexual Orientation
Streed C, Duncan M, Heier K, Workman T, Beach L, Caceres B, O'Leary J, Skanderson M, Goulet J. Prevalent Atherosclerotic Cardiovascular Disease Among Veterans by Sexual Orientation. Journal Of The American Heart Association 2024, 13: e036898. PMID: 39508159, PMCID: PMC11681393, DOI: 10.1161/jaha.124.036898.Peer-Reviewed Original ResearchPrevalent atherosclerotic cardiovascular diseasesAtherosclerotic cardiovascular diseaseIndex dateCardiovascular diseaseVeterans Health Administration dataPoor cardiovascular healthHealth administrative dataPrimary care appointmentsLGB veteransCardiovascular risk factorsCare appointmentsLogistic regression analysisSexual orientationCardiovascular healthVeteran populationHispanic ethnicityAdministrative dataNationwide cohortVeteransBaseline dateNatural language processing algorithmsSubstance useRisk factorsRegression analysisLanguage processing algorithmsThe Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis
Song J, Deshpande S, Chang Y, Chiang C, Ahn J, Lessa A, Soni A, Gonzales A, Lee P, Chang Y, Parker T, Kwan J, Chi K, Nanna M. The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis. Blood 2024, 144: 6869. DOI: 10.1182/blood-2024-194867.Peer-Reviewed Original ResearchGLP-1 RA usePropensity score matching analysisUrinary tract infectionSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase 4 inhibitorsGLP-1 RAsStandardized mean differenceType 2 DMMGUS diagnosisMGUS patientsAssociated with significant reductionsHeart failureRA useGLP-1Decompensated HFMyocardial infarctionMonoclonal gammopathyReceptor agonistsSecondary endpointsIndex dateCerebrovascular eventsDiabetes mellitusRetrospective propensity score-matched analysisIxekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Danve A, Vadhariya A, Lisse J, Cholayil A, Bansal N, Bello N, Bakewell C. Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study. Rheumatology And Therapy 2024, 11: 1333-1345. PMID: 39162898, PMCID: PMC11422398, DOI: 10.1007/s40744-024-00710-0.Peer-Reviewed Original ResearchHealth care resource utilizationFollow-up periodTumor necrosis factor-alpha inhibitorsTreatment patternsAxial spondyloarthritisPre-indexMethodsThis retrospective cohort studyBiologic-experienced patientsCharlson Comorbidity Index scoreRetrospective cohort studyClaims database studyIntroductionReal-world dataAssessed patient demographicsComorbidity Index scoreHigher comorbidity burdenProportion of daysBiologic-experiencedPatient demographicsClinical characteristicsIxekizumabIndex dateCohort studyPharmacy enrollmentEmergency room visitsAxSpADifferentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Erlandson K, Geng L, Selvaggi C, Thaweethai T, Chen P, Erdmann N, Goldman J, Henrich T, Hornig M, Karlson E, Katz S, Kim C, Cribbs S, Laiyemo A, Letts R, Lin J, Marathe J, Parthasarathy S, Patterson T, Taylor B, Duffy E, Haack M, Julg B, Maranga G, Hernandez C, Singer N, Han J, Pemu P, Brim H, Ashktorab H, Charney A, Wisnivesky J, Lin J, Chu H, Go M, Singh U, Levitan E, Goepfert P, Nikolich J, Hsu H, Peluso M, Kelly J, Okumura M, Flaherman V, Quigley J, Krishnan J, Scholand M, Hess R, Metz T, Costantine M, Rouse D, Taylor B, Goldberg M, Marshall G, Wood J, Warren D, Horwitz L, Foulkes A, McComsey G. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort. Annals Of Internal Medicine 2024, 177: 1209-1221. PMID: 39133923, PMCID: PMC11408082, DOI: 10.7326/m24-0737.Peer-Reviewed Original ResearchPostacute sequelae of SARS-CoV-2 infectionSARS-CoV-2 infectionLaboratory markersSARS-CoV-2Laboratory valuesUrinary albumin-creatinine ratioClinical laboratory markersStandard clinical laboratory testsAlbumin-creatinine ratioClinical laboratory valuesHemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>Clinically useful biomarkersClinical laboratory testsClinical laboratory measurementsPropensity score adjustmentSequelae of SARS-CoV-2 infectionPreexisting diabetesIndex dateMeasured 6 monthsClinical significanceNational Institutes of HealthStudy visitsEnrollment siteRisk factorsClinical biomarkers699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Mostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.Peer-Reviewed Original ResearchPost-index dateCharlson Comorbidity IndexModerate-to-severe ADMild AAModerate-to-severe AASevere AAModerate-to-severeAlopecia areataAtopic dermatitisMarketScan Commercial ClaimsTopical corticosteroidsAlopecia totalisReal-world prevalenceIndex dateAlopecia universalisHigh-potency topical corticosteroidsMonths post-index dateAA disease severityIncidence of atopic dermatitisHighest prevalencePotency topical corticosteroidsUS administrative claims databasePrevalence of AACox proportional hazards modelsAD comorbidityTransportation As A Determinant Of Health: Evaluating The Veterans Affairs Rideshare Program For Homeless Patients
Tsai J, Szymkowiak D, Beydoun H, Dasilva L. Transportation As A Determinant Of Health: Evaluating The Veterans Affairs Rideshare Program For Homeless Patients. Health Affairs 2024, 43: 1090-1099. PMID: 39102601, DOI: 10.1377/hlthaff.2023.01332.Peer-Reviewed Original ResearchConceptsHomeless service usersService usersService useVeterans AffairsAssociated with greater useHomeless patientsNational pilotMedical appointmentsAdministrative dataDepartment of Veterans AffairsVA administrative dataVA service useAttend medical appointmentsRidesharing programUrgent care visitsGreater useHealth systemInpatient servicesNationwide health systemCare visitsHomelessnessVulnerable patientsPatient transportIndex dateServicesMortality among veterans with epilepsy: Temporal significance of traumatic brain injury exposure
Roghani A, Wang C, Henion A, Amuan M, Altalib H, LaFrance W, Baca C, Van Cott A, Towne A, Kean J, Hinds S, Kennedy E, Panahi S, Pugh M. Mortality among veterans with epilepsy: Temporal significance of traumatic brain injury exposure. Epilepsia 2024, 65: 2255-2269. PMID: 39119799, DOI: 10.1111/epi.18026.Peer-Reviewed Original ResearchTraumatic brain injuryIndex dateTraumatic brain injury exposureDocumented traumatic brain injuryHazard ratioVeterans Health AdministrationConfidence intervalsTraumatic brain injury diagnosisPost-9/11 veteransDefense Health AgencyCox proportional hazards modelsAssociated with earlier timeProportional hazards modelRetrospective cohort studyHealth careHealth AdministrationHealth agenciesCumulative mortality rateInjury exposureMortality riskMortality hazardCohort studyVeteransSignificant mortality riskHazards modelCoronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink
Denoble A, Vazquez-Benitez G, Sheth S, Ackerman-Banks C, DeSilva M, Zhu J, Daley M, Getahun D, Klein N, Vesco K, Irving S, Nelson J, Williams J, Hambidge S, Donahue J, Weintraub E, Kharbanda E, Lipkind H. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstetrics And Gynecology 2024, 144: 215-222. PMID: 38843526, PMCID: PMC11250101, DOI: 10.1097/aog.0000000000005632.Peer-Reviewed Original ResearchVaccine Safety DatalinkAntepartum stillbirthVaccine Safety Datalink sitesLive birthsCOVID-19 vaccineVaccine dosePregnancy start dateRisk of severe morbidityRisk of stillbirthConditional logistic regressionCase-control studyVaccine manufacturersSingleton pregnanciesGestational ageFetal deathPostpartum visitMaternal ageIndex dateSevere morbidityDiagnostic codesPregnancyStillbirthPregnant peopleCOVID-19Logistic regressionBlood type as a risk factor for pancreatic ductal adenocarcinoma.
Rahimi Larki N, Skanderson M, Tate J, Levinson R, Hauser R, Brandt C, Yang Y, Justice A, Wang L. Blood type as a risk factor for pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 10559-10559. DOI: 10.1200/jco.2024.42.16_suppl.10559.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma riskVeterans Health AdministrationRisk of pancreatic ductal adenocarcinomaNon-O blood typeNeighborhood-level socioeconomic dataIntegrated healthcare systemHigh risk of pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAssociated with higher riskAssociated with increased riskUnited StatesHealth AdministrationOutpatient encountersHealthcare systemBaseline ageAlcohol useIndex dateAssociation of blood typeCancer deathWhite populationSocioeconomic dataBlack patientsDiverse populationsRisk factorsBlood type
2023
Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims. Blood 2023, 142: 2348. DOI: 10.1182/blood-2023-181909.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationHealthcare resource utilizationAcute myeloid leukemia patientsRetrospective cohort studyIndex dateMyeloid leukemia patientsAML patientsAML diagnosisR patientsDiagnosis codesEconomic burdenPPPM costsCohort studyContinuous enrollmentND patientsLeukemia patientsMedical costsLarge US administrative claims databaseRefractory acute myeloid leukemia patientsHigher healthcare resource utilizationUS administrative claims databaseMore outpatient encountersNon-HSCT patientsNon-transplant recipientsOlder AML patientsReal-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study
De Nigris E, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, Huntington S. Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study. Blood 2023, 142: 6523. DOI: 10.1182/blood-2023-178660.Peer-Reviewed Original ResearchB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsProportion of patientsCLL/SLLSmall lymphocytic lymphomaTyrosine kinase inhibitorsLymphocytic lymphomaNew agentsChronic lymphocytic leukemia/small lymphocytic lymphomaMedian age 73 yearsOptum Clinformatics DataMart databaseClinformatics DataMart databaseEnd of eligibilityObservation periodThird of patientsAge 73 yearsClaims-based algorithmChronic lymphocytic leukemiaTreatment classesReal-world studyNovel Bruton's tyrosine kinase inhibitorEligible patientsIndex dateAdult patientsTargeted agentsReal-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Costantino H, Modi K, Salimi T, Washington T, Epstein R. Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2023, 142: 548. DOI: 10.1182/blood-2023-188638.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeOral DECHMA therapyMedian ageTreatment patternsCCI scoreAML diagnosisMyelodysplastic syndromeSC cohortReal-world treatment patternsReal-world clinical practiceEnd of enrollmentMean CCI scorePre-index periodPrescription claims dataDiscontinuation of treatmentHalf of patientsDays of administrationStandard of careTreatment of MDSEnd of studyLongitudinal persistenceOral decitabineIndex dateTreatment cohortsReal-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data. Blood 2023, 142: 2428. DOI: 10.1182/blood-2023-178755.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAcute myeloid leukemiaNon-transplant recipientsR AML patientsIndex dateAML patientsOverall survivalTreatment patternsND patientsIntensive chemotherapyAML diagnosisR patientsDiagnosis codesTransplant recipientsOlder patientsSupportive careIntensive therapyContinuous enrollmentNovel therapiesLarge US administrative claims databaseUnmet needRefractory acute myeloid leukemia patientsReal-world treatment patternsUS administrative claims databaseAcute myeloid leukemia patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply